Clinical Trials connect scientific research carried out in the laboratory to clinical practice. All new therapies undergo rigorous evaluation to test for safety and effectiveness before the new treatment is used in the clinic.
Our medical oncologists such as Associate Professor Nick Pavlakis, Professor Stephen Clarke and Dr Helen Wheeler, in collaboration with Bill Walsh Lab scientists and other medical professionals, undertake Clinical Trials to promote the translation of new and innovative therapies into clinical practice for the benefit of cancer patients.
Clinical trials benefit patients and advance medical knowledge
Clinical trials are subject to regulatory controls to ensure the safety of participants
For information regarding clinical trials conducted at Royal North Shore Public Hospital – please contact Sally McCowatt ([email protected]).
1. “A Randomised Phase II Double-Blind Study of Regorafenib or Placebo in Refractory Advanced Oesophago-Gastric Cancer (AOGC)” (INTEGRATE)
Bill Walsh Lab Clinicians: A/Prof Nick Pavlakis, in collaboration with NHMRC Clinical Trial Centre and other clinical colleagues
Bill Walsh Lab Scientists: Dr Sarah Hayes, Dr Amanda Hudson, Mrs Rozelle Harvie, A/Prof Viive Howell
The INTEGRATE clinical trial evaluated the effect of a drug called regorafenib for treatment of advanced oesophago-gastric cancer. Translational work performed in the Bill Walsh Lab in partnership with the INTEGRATE trial involves identifying factors that predict for regorafenib efficacy and patient prognosis using cutting-edge proteomics and next-generation sequencing.
2. “A proof of concept study in ALK+ lung cancer of alternating lorlatinib with crizotinib after prior tyrosine kinase inhibitor therapy” (ALKternate)
Bill Walsh Lab Clinicians: A/Prof Nick Pavlakis, Dr Malinda Itchins, Prof Stephen Clarke, in collaboration with other clinical colleagues
Bill Walsh Lab Scientists: Dr Malinda Itchins, Dr Sarah Hayes, Dr Amanda Hudson, Mrs Rozelle Harvie, A/Prof Viive Howell
The ALKternate clinical trial is evaluating if alternating specific drugs for the treatment of a rare (ALK+) lung cancer will delay or overcome the development of drug resistance in these ALK+ patients. Translational work being done in the Bill Walsh Lab in partnership with the ALKternate clinical trial involves using proteomics and next-generation sequencing to identify changes in a patient’s blood or in cancer cell lines during alternating drug treatment to determine the optimal method in which to sequence these cancer treatments.